JNJ

NYSE

JOHNSON & JOHNSON

Latest disclosureSeptember 10, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 11 sales

Price by TradingView

Insider transactions 47

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

Showing the first 6 of 20 trades on this page.

Award disclosed

Daniel E. Pinto

Director

Deferred Share Units

Derivative security · not the ordinary share price.

Value context: $31.25K
Reported price: $276.31 / derivative unit

Award disclosed

Eugene A. Woods

Director

Deferred Share Units

Derivative security · not the ordinary share price.

Value context: $37.5K
Reported price: $276.31 / derivative unit

Award disclosed

Marillyn A. Hewson

Director

Deferred Share Units

Derivative security · not the ordinary share price.

Value context: $50K
Reported price: $276.31 / derivative unit

Exercise or conversion

Timothy Schmid

EVP, WW Chair, MedTech

Common Stock

Value context: $1.46M
Reported price: $131.94 / share

Exercise or conversion

Timothy Schmid

EVP, WW Chair, MedTech

Common Stock

Value context: $3.41M
Reported price: $151.41 / share

Exercise or conversion

Timothy Schmid

EVP, WW Chair, MedTech

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $131.94 exercise / conversion price

Understand this price

This row records an option exercise or conversion. The derivative transaction price is separate from the exercise price; it is not the stock's market price. Its row value is not shown as another stock purchase.

Exercise or conversion

Timothy Schmid

EVP, WW Chair, MedTech

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $151.41 exercise / conversion price

Understand this price

Exercise or conversion

Jennifer L. Taubert

EVP, WWC. Innovative Medicine

Common Stock

Value context: $1.74M
Reported price: $115.67 / share

Exercise or conversion

Jennifer L. Taubert

EVP, WWC. Innovative Medicine

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $115.67 exercise / conversion price

Understand this price

Exercise or conversion

Joaquin Duato

CEO and Chairman of the Board

Common Stock

Value context: $14.26M
Reported price: $115.67 / share

Exercise or conversion

Joaquin Duato

CEO and Chairman of the Board

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $115.67 exercise / conversion price

Understand this price

Exercise or conversion

Elizabeth Forminard

EVP, Chief Legal Officer

Common Stock

Value context: $1.23M
Reported price: $131.94 / share

Exercise or conversion

Elizabeth Forminard

EVP, Chief Legal Officer

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $131.94 exercise / conversion price

Understand this price

Exercise or conversion

Vanessa Broadhurst

EVP, Global Corp Affairs

Common Stock

Value context: $1.44M
Reported price: $129.51 / share

Exercise or conversion

Vanessa Broadhurst

EVP, Global Corp Affairs

Common Stock

Value context: $1.57M
Reported price: $131.94 / share

Exercise or conversion

Vanessa Broadhurst

EVP, Global Corp Affairs

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $129.51 exercise / conversion price

Understand this price

Exercise or conversion

Vanessa Broadhurst

EVP, Global Corp Affairs

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $131.94 exercise / conversion price

Understand this price

Exercise or conversion

Kathryn E. Wengel

EVP, Chief TO and Risk Officer

Common Stock

Value context: $1.16M
Reported price: $115.67 / share

Exercise or conversion

Kathryn E. Wengel

EVP, Chief TO and Risk Officer

Employee Stock Options (Right to Buy)

Derivative security · not the ordinary share price.

Value context: Not a separate purchase
Exercise / conversion price: $115.67 exercise / conversion price

Understand this price

Award disclosed

Eugene A. Woods

Director

Deferred Share Units

Derivative security · not the ordinary share price.

Value context: $37.5K
Reported price: $232.79 / derivative unit

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
Director	Deferred Share UnitsGrant or award	Derivative units113$276.31 / derivative unit	$31.25K	Sep 8Filed Sep 10 · 2d later	SEC filing
Director	Deferred Share UnitsGrant or award	Derivative units136$276.31 / derivative unit	$37.5K	Sep 8Filed Sep 10 · 2d later	SEC filing
Director	Deferred Share UnitsGrant or award	Derivative units181$276.31 / derivative unit	$50K	Sep 8Filed Sep 10 · 2d later	SEC filing
EVP, WW Chair, MedTech	Common StockOption exercise or conversion	11,070$131.94 / share	$1.46M	Sep 2Filed Sep 4 · 2d later	SEC filing
EVP, WW Chair, MedTech	Common StockOption exercise or conversion	22,527$151.41 / share	$3.41M	Sep 2Filed Sep 4 · 2d later	SEC filing
EVP, WW Chair, MedTech	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units11,070$131.94 exercise / conversion price	Not a separate purchase	Sep 2Filed Sep 4 · 2d later	SEC filing
EVP, WW Chair, MedTech	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units22,527$151.41 exercise / conversion price	Not a separate purchase	Sep 2Filed Sep 4 · 2d later	SEC filing
EVP, WWC. Innovative Medicine	Common StockOption exercise or conversion	15,000$115.67 / share	$1.74M	Aug 17Filed Aug 18 · 1d later	SEC filing
EVP, WWC. Innovative Medicine	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units15,000$115.67 exercise / conversion price	Not a separate purchase	Aug 17Filed Aug 18 · 1d later	SEC filing
CEO and Chairman of the Board	Common StockOption exercise or conversion	123,291$115.67 / share	$14.26M	Aug 13Filed Aug 14 · 1d later	SEC filing
CEO and Chairman of the Board	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units123,291$115.67 exercise / conversion price	Not a separate purchase	Aug 13Filed Aug 14 · 1d later	SEC filing
EVP, Chief Legal Officer	Common StockOption exercise or conversion	9,344$131.94 / share	$1.23M	Aug 6Filed Aug 7 · 1d later	SEC filing
EVP, Chief Legal Officer	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units9,344$131.94 exercise / conversion price	Not a separate purchase	Aug 6Filed Aug 7 · 1d later	SEC filing
EVP, Global Corp Affairs	Common StockOption exercise or conversion	11,129$129.51 / share	$1.44M	Jul 20Filed Jul 21 · 1d later	SEC filing
EVP, Global Corp Affairs	Common StockOption exercise or conversion	11,925$131.94 / share	$1.57M	Jul 20Filed Jul 21 · 1d later	SEC filing
EVP, Global Corp Affairs	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units11,129$129.51 exercise / conversion price	Not a separate purchase	Jul 20Filed Jul 21 · 1d later	SEC filing
EVP, Global Corp Affairs	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units11,925$131.94 exercise / conversion price	Not a separate purchase	Jul 20Filed Jul 21 · 1d later	SEC filing
EVP, Chief TO and Risk Officer	Common StockOption exercise or conversion	10,000$115.67 / share	$1.16M	Jun 11Filed Jun 12 · 1d later	SEC filing
EVP, Chief TO and Risk Officer	Employee Stock Options (Right to Buy)Option exercise or conversion	Derivative units10,000$115.67 exercise / conversion price	Not a separate purchase	Jun 11Filed Jun 12 · 1d later	SEC filing
Director	Deferred Share UnitsGrant or award	Derivative units161$232.79 / derivative unit	$37.5K	Jun 9Filed Jun 11 · 2d later	SEC filing

Showing the latest 20 of 36 trades. Show all 36 trades

Congress transactions 29

All Congress filings

Purchase disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a purchase for the member.

Lloyd DoggettReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: September 8, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Thomas H. Kean JrReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: August 27, 2026

Partial sale disclosed

Johnson & Johnson Common Stock · Stock

The filing reports a partial sale for a joint account.

John BoozmanReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: August 20, 2026

Sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a sale for the member.

Richard Dean Dr McCormick official portrait

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: July 30, 2026

Full sale disclosedAmended report

Johnson & Johnson Common Stock · Stock

The filing reports a full sale for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: October 29, 2024

Full sale disclosedAmended report

Johnson & Johnson Common Stock · Stock

The filing reports a full sale for a joint account.

Thomas H TubervilleReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: October 29, 2024

Purchase disclosed

Johnson & Johnson Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 30, 2026

Purchase disclosed

Johnson & Johnson Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: March 27, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Thomas H. Kean JrReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: June 29, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Thomas H. Kean JrReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: June 2, 2026

Purchase disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a purchase for the member.

Lloyd DoggettReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: June 9, 2026

Partial sale disclosed

Johnson & Johnson Common Stock · Stock

The filing reports a partial sale for a joint account.

John BoozmanReporting Senate member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 19, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Thomas H. Kean JrReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 26, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 19, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 19, 2026

Purchase disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a purchase for the member.

Lloyd DoggettReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: March 10, 2026

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Thomas H. Kean JrReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: January 23, 2026

Sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 18, 2025

Purchase disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a purchase for the member.

Lloyd DoggettReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 9, 2025

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for the member.

Thomas H. Kean JrReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: November 20, 2025

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 13, 2025

Purchase disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a purchase for the member.

Richard Dean Dr McCormickReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 5, 2025

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for a dependent.

Jared MoskowitzReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 10, 2025

Partial sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a partial sale for a dependent.

Jared MoskowitzReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 10, 2025

Sale disclosed

Johnson & Johnson Common Stock (JNJ) · Stock

The filing reports a sale for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 31, 2025

Showing the latest 25 of 29 disclosed trades. Show all 29 trades

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000200406
Latest public acceptance: Sep 11, 2026, 12:51 AM UTC
Score calculated: Oct 7, 2026, 12:04 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

Director

Deferred Share UnitsGrant or award

Derivative units113$276.31 / derivative unit

$31.25K

Sep 8Filed Sep 10 · 2d later

SEC filing

Director

Deferred Share UnitsGrant or award

Derivative units136$276.31 / derivative unit

$37.5K

Sep 8Filed Sep 10 · 2d later

SEC filing

Director

Deferred Share UnitsGrant or award

Derivative units181$276.31 / derivative unit

$50K

Sep 8Filed Sep 10 · 2d later

SEC filing

EVP, WW Chair, MedTech

Common StockOption exercise or conversion

11,070$131.94 / share

$1.46M

Sep 2Filed Sep 4 · 2d later

SEC filing

EVP, WW Chair, MedTech

Common StockOption exercise or conversion

22,527$151.41 / share

$3.41M

Sep 2Filed Sep 4 · 2d later

SEC filing

EVP, WW Chair, MedTech

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units11,070$131.94 exercise / conversion price

Not a separate purchase

Sep 2Filed Sep 4 · 2d later

SEC filing

EVP, WW Chair, MedTech

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units22,527$151.41 exercise / conversion price

Not a separate purchase

Sep 2Filed Sep 4 · 2d later

SEC filing

EVP, WWC. Innovative Medicine

Common StockOption exercise or conversion

15,000$115.67 / share

$1.74M

Aug 17Filed Aug 18 · 1d later

SEC filing

EVP, WWC. Innovative Medicine

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units15,000$115.67 exercise / conversion price

Not a separate purchase

Aug 17Filed Aug 18 · 1d later

SEC filing

CEO and Chairman of the Board

Common StockOption exercise or conversion

123,291$115.67 / share

$14.26M

Aug 13Filed Aug 14 · 1d later

SEC filing

CEO and Chairman of the Board

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units123,291$115.67 exercise / conversion price

Not a separate purchase

Aug 13Filed Aug 14 · 1d later

SEC filing

EVP, Chief Legal Officer

Common StockOption exercise or conversion

9,344$131.94 / share

$1.23M

Aug 6Filed Aug 7 · 1d later

SEC filing

EVP, Chief Legal Officer

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units9,344$131.94 exercise / conversion price

Not a separate purchase

Aug 6Filed Aug 7 · 1d later

SEC filing

EVP, Global Corp Affairs

Common StockOption exercise or conversion

11,129$129.51 / share

$1.44M

Jul 20Filed Jul 21 · 1d later

SEC filing

EVP, Global Corp Affairs

Common StockOption exercise or conversion

11,925$131.94 / share

$1.57M

Jul 20Filed Jul 21 · 1d later

SEC filing

EVP, Global Corp Affairs

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units11,129$129.51 exercise / conversion price

Not a separate purchase

Jul 20Filed Jul 21 · 1d later

SEC filing

EVP, Global Corp Affairs

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units11,925$131.94 exercise / conversion price

Not a separate purchase

Jul 20Filed Jul 21 · 1d later

SEC filing

EVP, Chief TO and Risk Officer

Common StockOption exercise or conversion

10,000$115.67 / share

$1.16M

Jun 11Filed Jun 12 · 1d later

SEC filing

EVP, Chief TO and Risk Officer

Employee Stock Options (Right to Buy)Option exercise or conversion

Derivative units10,000$115.67 exercise / conversion price

Not a separate purchase

Jun 11Filed Jun 12 · 1d later

SEC filing

Director

Deferred Share UnitsGrant or award

Derivative units161$232.79 / derivative unit

$37.5K

Jun 9Filed Jun 11 · 2d later

SEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0000200406
Latest public acceptance: Sep 11, 2026, 12:51 AM UTC
Score calculated: Oct 7, 2026, 12:04 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.